Fate Therapeutics (FATE) Price & Analysis

Compare

1,249 Followers

FATE Stock Chart & Stats

$0.96

-$0.10(-5.71%)

At close: Jan 08 4:00 PM EST

$0.96

-$0.10(-5.71%)

Day’s Range― - ―

52-Week Range$0.66 - $3.43

Previous CloseN/A

Volume630.90K

Average Volume (3M)2.52M

Market Cap

$111.20M

Enterprise Value$13.76M

Total Cash (Recent Filing)$215.42M

Total Debt (Recent Filing)$79.25M

Price to Earnings (P/E)―

Beta2.24

Next Earnings

Mar 02, 2026

EPS Estimate

-0.27

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.27

Shares Outstanding115,352,290

10 Day Avg. Volume2,018,621

30 Day Avg. Volume2,516,364

Financial Highlights & Ratios

PEG Ratio0.00

Price to Book (P/B)0.59

Price to Sales (P/S)13.76

P/FCF Ratio-1.52

Enterprise Value/Market Cap0.12

Enterprise Value/Revenue1.93

Enterprise Value/Gross Profit1.93

Enterprise Value/Ebitda-0.10

Forecast

1Y Price Target

$5.29

Price Target Upside451.04% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering9

EPS Forecast (FY)-1.15

Revenue Forecast (FY)$6.52M

Bulls Say, Bears Say

Bulls Say

Clinical AdvancementsFT819 demonstrated rapid and durable improvements in SLEDAI, PGA, and UPCR scores with marked fatigue relief, despite fludarabine-free or no conditioning and no high-grade CRS, ICANS, or GvHD.

Financial StabilityFATE has extended its cash runway through early 2028, indicating financial stability to support ongoing operations.

Regulatory ApprovalsFate has received regulatory approval from both the UK's MHRA and the EU's EMA to begin clinical trials of FT819 for autoimmune diseases.

Bears Say

Clinical RisksRisks include failure to demonstrate a meaningful clinical efficacy advantage with FT819 relative to other allogeneic and autologous CAR-T approaches.

Mixed Clinical ResultsRecent update showed mixed durability relating to B-cell aplasia, especially in patients who received no conditioning.

Patient Response ConcernsOne of the initially dosed patients showed disease relapse at 12 months.

Fate Therapeutics News

Fate Therapeutics reports Q3 EPS (27c), consensus (28c)

Reports Q3 revenue $1.741M, consensus $1.68M. “The potentially transformative impact of FT819 in lupus is at an inflection...

6d ago

FATE

Fate Therapeutics upgraded to Buy from Neutral at H.C. Wainwright

H.C. Wainwright analyst Robert Burns upgraded Fate Therapeutics (FATE) to Buy from Neutral with a $5 price target...

19d ago

FATE

Wedbush upgrades Fate Therapeutics to Outperform, raises target to $7

As previously reported, Wedbush analyst Martin Fan upgraded Fate Therapeutics (FATE) to Outperform from Neutral with a price...

23d ago

FATE

Fate Therapeutics upgraded to Outperform from Neutral at Wedbush

Wedbush upgraded Fate Therapeutics (FATE) to Outperform from Neutral with a price target of $7, up from $5....

23d ago

FATE

Fate Therapeutics Reports Q3 Loss Amid Restructuring Efforts

Fate Therapeutics Inc ( ($FATE) ) has released its Q3 earnings. Here is a breakdown of the information...

2d ago

FATE

Navigating Data Privacy Challenges: Fate Therapeutics’ Battle with Regulatory Compliance and Business Risks

Fate Therapeutics Inc (FATE) has disclosed a new risk, in the Environmental / Social category. Fate Therapeutics Inc....

4d ago

FATE

Fate Therapeutics: Balancing Potential and Uncertainty with FT819’s Promise in Autoimmune Treatment

TD Cowen analyst Tara Bancroft has maintained their neutral stance on FATE stock, giving a Hold rating on...

6d ago

FATE

Is FATE a Buy, Before Earnings?

Fate Therapeutics Inc (FATE) is scheduled to report 3rd quarter earnings on 10/30/2025. Regarding Q3 estimates, Wall Street...

22d ago

FATE

Fate Therapeutics Advances CAR T-Cell Therapy with New Clinical Study

Fate Therapeutics Inc (($FATE)) announced an update on their ongoing clinical study. Fate Therapeutics Inc. is conducting a...

23d ago

FATE

Fate Therapeutics’ Phase 1 Study: A Potential Game-Changer in Autoimmune Disease Treatment

Fate Therapeutics Inc (($FATE)) announced an update on their ongoing clinical study. Study Overview: Fate Therapeutics Inc. is...

23d ago

FATE

Fate Therapeutics’ Innovative CAR T-Cell Therapy Study: A Potential Game-Changer in Cancer Treatment

Fate Therapeutics Inc (($FATE)) announced an update on their ongoing clinical study. Fate Therapeutics Inc. is conducting a...

23d ago

FATE

Fate Therapeutics Reports Promising Phase 1 Trial Results

The latest update is out from Fate Therapeutics ( ($FATE) ). On October 26, 2025, Fate Therapeutics announced...

23d ago

FATE

Hold Rating Maintained for Fate Therapeutics’ FT819 Amid Efficacy and Durability Concerns

Needham analyst Gil Blum has maintained their neutral stance on FATE stock, giving a Hold rating on October...

24d ago

FATE

Fate Therapeutics Appoints New CFO Kamal Adawi

Fate Therapeutics ( ($FATE) ) has issued an announcement. On October 10, 2025, John D. Mendlein and Neelufar...

1M ago

FATE

FATE FAQ

What was Fate Therapeutics Inc’s price range in the past 12 months?

Fate Therapeutics Inc lowest stock price was $0.66 and its highest was $3.43 in the past 12 months.

What is Fate Therapeutics Inc’s market cap?

Fate Therapeutics Inc’s market cap is $111.20M.

When is Fate Therapeutics Inc’s upcoming earnings report date?

Fate Therapeutics Inc’s upcoming earnings report date is Mar 02, 2026 which is in 103 days.

How were Fate Therapeutics Inc’s earnings last quarter?

Fate Therapeutics Inc released its earnings results on Nov 13, 2025. The company reported -$0.27 earnings per share for the quarter, beating the consensus estimate of -$0.292 by $0.022.

Is Fate Therapeutics Inc overvalued?

According to Wall Street analysts Fate Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Fate Therapeutics Inc pay dividends?

Fate Therapeutics Inc does not currently pay dividends.

What is Fate Therapeutics Inc’s EPS estimate?

Fate Therapeutics Inc’s EPS estimate is -0.27.

How many shares outstanding does Fate Therapeutics Inc have?

Fate Therapeutics Inc has 115,352,290 shares outstanding.

What happened to Fate Therapeutics Inc’s price movement after its last earnings report?

Fate Therapeutics Inc reported an EPS of -$0.27 in its last earnings report, beating expectations of -$0.292. Following the earnings report the stock price went down -4.615%.

Which hedge fund is a major shareholder of Fate Therapeutics Inc?

Currently, no hedge funds are holding shares in FATE

Fate Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-52.35%

Trailing 12-Months

Asset Growth

-30.57%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Fate Therapeutics Inc

Fate Therapeutics, Inc. is a biotechnology company focused on developing innovative cell-based therapies for cancer and immune disorders. The company operates primarily in the regenerative medicine sector, leveraging its proprietary induced pluripotent stem cell (iPSC) platform to create off-the-shelf cellular therapies that are designed to enhance the immune system's ability to combat diseases. Key products in their pipeline include various engineered cell therapies intended for the treatment of hematologic malignancies and solid tumors, as well as applications in hematopoietic cell transplantation and autoimmune diseases.

Fate Therapeutics (FATE) Earnings & Revenues

Historic Earnings Reports

FATE Stock 12 Month Forecast

Average Price Target

$5.29

▲(451.04% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","9":"$9","-1":"-$1","1.5":"$1.5","6.5":"$6.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$5.29</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.5,4,6.5,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.35,1.8615384615384616,2.3730769230769235,2.884615384615385,3.3961538461538465,3.907692307692308,4.41923076923077,4.930769230769231,5.442307692307693,5.953846153846154,6.465384615384616,6.976923076923077,7.488461538461539,{"y":8,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.35,1.653076923076923,1.9561538461538461,2.2592307692307694,2.5623076923076926,2.8653846153846154,3.1684615384615387,3.4715384615384615,3.7746153846153847,4.077692307692308,4.38076923076923,4.683846153846154,4.986923076923077,{"y":5.29,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.35,1.4000000000000001,1.4500000000000002,1.5,1.55,1.6,1.6500000000000001,1.7000000000000002,1.75,1.8,1.85,1.9,1.9500000000000002,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.43,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.96,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.65,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.3,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.12,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.757,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.24,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.3,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.14,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.07,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.03,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.25,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.35,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >